

Cultural Linguistic Competency (CLC) and Implicit Bias (IB)

The California legislature has passed [Assembly Bill \(AB\) 1195](#), which states that as of July 1, 2006, all Category 1 CME activities that relate to patient care must include a cultural diversity/linguistics component. It has also passed [AB 241](#), which states that as of January 1, 2022, all continuing education courses for a physician and surgeon **must** contain curriculum that includes specified instruction in the understanding of implicit bias in medical treatment.

The cultural and linguistic competency (CLC) and implicit bias (IB) definitions reiterate how patients' diverse backgrounds may impact their access to care.

The following bibliography of articles is provided to serve as a resource and adjunct to this activity.

1. [Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction.](#)
Sun LF, Maples KT, Hall KH, Liu Y, Cao Y, Joseph NS, Hofmeister CC, Kaufman JL, Dhodapkar M, Nooka AK, Lonial S, Harvey RD.
JCO Oncol Pract. 2023 Sep;19(9):793-798. doi: 10.1200/OP.22.00781. Epub 2023 Jul 7.
PMID: 37418682
2. [Tramadol for neuropathic pain in adults.](#)
Duehmke RM, Derry S, Wiffen PJ, Bell RF, Aldington D, Moore RA.
Cochrane Database Syst Rev. 2017 Jun 15;6(6):CD003726. doi:
10.1002/14651858.CD003726.pub4.
PMID: 28616956 Review.
3. [Patient Characteristics Associated With Chemotherapy-Induced Peripheral Neuropathy Severity in a Phase II Clinical Trial: A Retrospective Analysis.](#)
Zhi WI, Dreyfus N, Lessing A, Galantino M, Piulson L, Kot KL, Li S, Bao T.
Oncologist. 2023 Jul 5;28(7):604-608. doi: 10.1093/oncolo/oyad062.
PMID: 36972359 Clinical Trial.
4. [The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy \(CIPN\) in colorectal cancer: secondary analysis of the SCOT trial.](#)
Lemanska A, Harkin A, Iveson T, Kelly C, Saunders M, Faithfull S.
ESMO Open. 2023 Dec;8(6):102063. doi: 10.1016/j.esmoop.2023.102063. Epub 2023 Nov 20.
PMID: 37988949 Clinical Trial.
5. [Exploring Outcome Priorities and Real-Life Management of Chemotherapy-Induced Peripheral Neurotoxicity: A Survey of the Italian Association for the Study of Pain members.](#)
Sardo S, Varrassi G, Scartozzi M, Pace MC, Schweiger V, Tamburin S, Musu M, Finco G.
J Pain Res. 2023 Sep 25;16:3227-3238. doi: 10.2147/JPR.S414389. eCollection 2023.
PMID: 37790191